Literature DB >> 22547352

Comparison of standard- and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins.

Andrew J Percy1, Andrew G Chambers, Juncong Yang, Dominik Domanski, Christoph H Borchers.   

Abstract

The analytical performance of a standard-flow ultra-high-performance liquid chromatography (UHPLC) and a nano-flow high-performance liquid chromatography (HPLC) system, interfaced to the same state-of-the-art triple-quadrupole mass spectrometer, were compared for the multiple reaction monitoring (MRM)-mass spectrometry (MS)-based quantitation of a panel of 48 high-to-moderate-abundance cardiovascular disease-related plasma proteins. After optimization of the MRM transitions for sensitivity and testing for chemical interference, the optimum sensitivity, loading capacity, gradient, and retention-time reproducibilities were determined. We previously demonstrated the increased robustness of the standard-flow platform, but we expected that the standard-flow platform would have an overall lower sensitivity. This study was designed to determine if this decreased sensitivity could be compensated for by increased sample loading. Significantly fewer interferences with the MRM transitions were found for the standard-flow platform than for the nano-flow platform (2 out of 103 transitions compared with 42 out of 103 transitions, respectively), which demonstrates the importance of interference-testing when nano-flow systems are used. Using only interference-free transitions, 36 replicate LC/MRM-MS analyses resulted in equal signal reproducibilities between the two platforms (9.3 % coefficient of variation (CV) for 88 peptide targets), with superior retention-time precision for the standard-flow platform (0.13 vs. 6.1 % CV). Surprisingly, for 41 of the 81 proteotypic peptides in the final assay, the standard-flow platform was more sensitive while for 9 of 81 the nano-flow platform was more sensitive. For these 81 peptides, there was a good correlation between the two sets of results (R(2) = 0.98, slope = 0.97). Overall, the standard-flow platform had superior performance metrics for most peptides, and is a good choice if sufficient sample is available.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22547352     DOI: 10.1007/s00216-012-6010-y

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  18 in total

1.  Multiplexed quantitation of endogenous proteins in dried blood spots by multiple reaction monitoring-mass spectrometry.

Authors:  Andrew G Chambers; Andrew J Percy; Juncong Yang; Alexander G Camenzind; Christoph H Borchers
Journal:  Mol Cell Proteomics       Date:  2012-12-07       Impact factor: 5.911

Review 2.  Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.

Authors:  Carol E Parker; Christoph H Borchers
Journal:  Mol Oncol       Date:  2014-03-20       Impact factor: 6.603

3.  Simultaneous Enrichment of Plasma Soluble and Extracellular Vesicular Glycoproteins Using Prolonged Ultracentrifugation-Electrostatic Repulsion-hydrophilic Interaction Chromatography (PUC-ERLIC) Approach.

Authors:  Esther Sok Hwee Cheow; Kae Hwan Sim; Dominique de Kleijn; Chuen Neng Lee; Vitaly Sorokin; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2015-04-10       Impact factor: 5.911

4.  Discovery and targeted proteomics on cutaneous biopsies infected by borrelia to investigate lyme disease.

Authors:  Gilles Schnell; Amandine Boeuf; Benoît Westermann; Benoît Jaulhac; Dan Lipsker; Christine Carapito; Nathalie Boulanger; Laurence Ehret-Sabatier
Journal:  Mol Cell Proteomics       Date:  2015-02-24       Impact factor: 5.911

5.  Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.

Authors:  Daniel S Spellman; Kristin R Wildsmith; Lee A Honigberg; Marianne Tuefferd; David Baker; Nandini Raghavan; Angus C Nairn; Pascal Croteau; Michael Schirm; Rene Allard; Julie Lamontagne; Daniel Chelsky; Steven Hoffmann; William Z Potter
Journal:  Proteomics Clin Appl       Date:  2015-04-24       Impact factor: 3.494

6.  Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides.

Authors:  Romain Simon; Marion Girod; Catherine Fonbonne; Arnaud Salvador; Yohann Clément; Pierre Lantéri; Philippe Amouyel; Jean Charles Lambert; Jérôme Lemoine
Journal:  Mol Cell Proteomics       Date:  2012-08-23       Impact factor: 5.911

7.  Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma.

Authors:  Alok K Shah; Kim-Anh Lê Cao; Eunju Choi; David Chen; Benoît Gautier; Derek Nancarrow; David C Whiteman; Nicholas A Saunders; Andrew P Barbour; Virendra Joshi; Michelle M Hill
Journal:  Mol Cell Proteomics       Date:  2015-09-24       Impact factor: 5.911

8.  A label-free selected reaction monitoring workflow identifies a subset of pregnancy specific glycoproteins as potential predictive markers of early-onset pre-eclampsia.

Authors:  Richard T Blankley; Christal Fisher; Melissa Westwood; Robyn North; Philip N Baker; Michael J Walker; Andrew Williamson; Anthony D Whetton; Wanchang Lin; Lesley McCowan; Claire T Roberts; Garth J S Cooper; Richard D Unwin; Jenny E Myers
Journal:  Mol Cell Proteomics       Date:  2013-07-29       Impact factor: 5.911

9.  Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry.

Authors:  Michael A Gillette; Steven A Carr
Journal:  Nat Methods       Date:  2013-01       Impact factor: 28.547

10.  The Human Proteome Organization Chromosome 6 Consortium: integrating chromosome-centric and biology/disease driven strategies.

Authors:  C H Borchers; J Kast; L J Foster; K W M Siu; C M Overall; T A Binkowski; W H Hildebrand; A Scherer; M Mansoor; P A Keown
Journal:  J Proteomics       Date:  2013-08-08       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.